Skinovation Pharmaceutical Inc financial data

Location
440 East 400 South, Ste 300, Salt Lake City, UT
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 21, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.9 % +78.1%
Debt-to-equity -102 % -0.85%
Return On Equity 9.65 % +18.3%
Return On Assets -499 % +34.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 708K shares
Common Stock, Shares, Outstanding 708K shares 0%
Entity Public Float 0 USD
Common Stock, Value, Issued 708 USD 0%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 22.3K USD +55.5%
Operating Income (Loss) -22.3K USD -55.5%
Net Income (Loss) Attributable to Parent -45K USD -29.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.84K USD -80.9%
Assets, Current 1.84K USD -80.9%
Assets 1.84K USD -80.9%
Accounts Payable, Current 10.5K USD 0%
Liabilities, Current 485K USD +8.31%
Liabilities 485K USD +8.31%
Retained Earnings (Accumulated Deficit) -509K USD -9.7%
Stockholders' Equity Attributable to Parent -483K USD -10.3%
Liabilities and Equity 1.84K USD -80.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.5K USD +17.1%
Net Cash Provided by (Used in) Financing Activities 9K USD +80%
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 708K shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.5K USD -173%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.84K USD -80.9%
Deferred Tax Assets, Valuation Allowance 99.3K USD +8.2%
Deferred Tax Assets, Operating Loss Carryforwards 99.3K USD +8.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Additional Paid in Capital 25.1K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 22.7K USD +11.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%